Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 1100-1104

  Sankilampi, Ulla ^a   Honkanen, Pekka O ^b   Bloigu, Aini ^b   Leinonen, Maija ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

AGE; AGED; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVACCINATION; SEROTYPE; SEX DIFFERENCE; STREPTOCOCCUS INFECTION;

EID: 0030763924     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516521     Document Type: Article

References (14)

1. Centers for Disease Control. Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1989;38:73-6.
2. Borgoño JM, McLean AA, Vella PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978; 157:148-54.
3. Mufson MA, Hughey DF, Turner CE, Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991;9:403-7.
4. Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 1993; 17:66-73.
5. Davidson M, Bulkow LR, Grabman J, et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994;154:2209-14.
6. Honkanen PO, Keistinen T, Kivelä S. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996; 156:205-8.
7. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996;173:387-93.
8. Mäkelā PH, Eskola J, Käyhty H, Takala AK. Vaccines against Haemophilus influenzae type b. In: Ala'Aldeen DAA, Hormaeche CE, eds. Molecular and clinical aspects of bacterial vaccine development. New York: John Wiley & Sons, 1995:42-91.
9. Mufson MA, Krause HE, Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med 1983;173:270-5.
10. Mufson MA, Krause HE, Schiffman G, Hughey DF. Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci 1987;293:279-84.
11. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270:1826-31.
12. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325: 1453-60.
13. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WFI. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;106:1-6.
14. Sankilampi U, Honkanen PO, Pyhälä R, Leinonen M. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine (in press).